Non-insulin oral drug(s)-Trajenta (Linagliptin) Posts on Medivizor
Navigation Menu

Non-insulin oral drug(s)-Trajenta (Linagliptin) Posts on Medivizor

DPP-4 inhibitor use in type 2 diabetes and the risk of diabetic eye disease

Posted by on Dec 8, 2018 in Diabetes mellitus | 0 comments

In a nutshell This study aimed to investigate if the use of DPP-4 inhibitor drugs for the treatment of type 2 diabetes (T2D) was harmful or helpful in diabetic retinopathy (DR; eye disease). The main finding of this study was that DPP-4 inhibitors did not increase the overall risk of DR. Some background DPP-4 inhibitors (DPP4i) are a type drug used to...

Read More

Dipeptidyl peptidase-4 inhibitors are not associated with increased cancer risk

Posted by on Nov 8, 2017 in Diabetes mellitus | 0 comments

In a nutshell This study reviewed data on the association between dipeptidyl peptidase-4 (DPP4) inhibitors and cancer development in patients with type 2 diabetes. They found that patients receiving DPP4 inhibitors were not at a greater risk of developing cancer.  Some background Management of type 2 diabetes requires stringent blood...

Read More

Is empagliflozin effective as an add-on therapy in uncontrolled type 2 diabetes?

Posted by on Jul 9, 2017 in Diabetes mellitus | 0 comments

In a nutshell This study determined the suitability of adding empagliflozin (Jardiance) to the combination of metformin (Glucophage) and linaglipton (Tradjenta) in type 2 diabetes. The authors concluded that adding empagliflozin was effective in patients whose blood sugar was not controlled by the combination of metformin and linaglipton alone. Some...

Read More

Safety and efficacy of linagliptin in patients with type 2 diabetes with liver complications

Posted by on Oct 17, 2016 in Diabetes mellitus | 0 comments

In a nutshell The authors aimed to determine the effect and safety of linagliptin (Tradjenta) in patients with type 2 diabetes with liver disease. The authors concluded that linagliptin is an effective and safe treatment in patients with type 2 diabetes and liver disease. Some background Diabetes raises the risk of non-alcohol...

Read More

Linagliptin (Tradjenta) – an effective and safe treatment for type 2 diabetics with kidney dysfunction

Posted by on Jun 25, 2015 in Diabetes mellitus | 0 comments

In a nutshell This study aimed to determine the effectiveness and safety of linagliptin treatment in patients with mild and moderate kidney dysfunction. Some background Approximately 40% of diabetics develop kidney disease. This is associated with a higher risk of developing cardiovascular dysfunction (heart-related illness) and...

Read More